(616 Kb) Link

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications (616 KB)

The study highlighted a few differences between "real-world" patients and those in trials:

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials The researchers analyzed a large group of 616

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .

: For those who stopped the medication, the median time until they did so was only 7 months . If you'd like, I can: : Both groups

: Finding ways to help patients manage side effects so they can stay on the therapy longer.